At 4.6% CAGR, the North America Endothelial Dysfunction Market is Projected to be Worth US$ 1,247.30 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the North America endothelial dysfunction market was valued at US$ 951.83 million in 2022 and is expected to reach US$ 1,247.30 million by 2028, registering a CAGR of 4.6% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes and obesity are the critical factors attributed to the North America endothelial dysfunction market expansion.                     

Endothelial dysfunction is a strong prognostic factor for cardiovascular events and mortality in the population. Assessment of endothelial function can aid in selecting therapies and assessing their response. While invasive angiography remains the gold standard for measuring coronary endothelial function, several noninvasive imaging techniques have evolved to study both coronary and peripheral endothelial function. Available endothelial testing methods are helpful for mechanistically understanding diseases and risk stratification and prognoses, such as high-resolution B-mode ultrasound and Doppler, computed tomography angiography, cardiovascular magnetic resonance (CMR), magnetic resonance imaging (MRI), and positron emission tomography (PET). Noninvasive methods for assessing endothelial function are mainly used in scientific research since there is a significant risk of complications due to the specificity of endovascular interventions. One of the noninvasive methods to assess endothelial function is to measure fluorescence. Flow-mediated skin fluorescence (FMSF) is based on the fluorescence measurement of the reduced nicotinamide adenine dinucleotide (NADH) emitted by skin cells in response to UV light excitation. The test consists of three phases: recording the fluorescence's background intensity, occlusion phase, and reaction registration.

On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of North America endothelial dysfunction market.

Based on cause, the North America endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment held 33.1% share of North America endothelial dysfunction market in 2022, amassing US$ 315.17 million. It is projected to garner US$ 424.42 million by 2028 to expand at 5.1% CAGR during 2022–2028.

Based on test type, the North America endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 73.9% share of North America endothelial dysfunction market in 2022, amassing US$ 703.86 million. It is projected to garner US$ 908.51 million by 2028 to expand at 4.4% CAGR during 2022–2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the North America endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held 51.8% share of North America endothelial dysfunction market in 2022, amassing US$ 493.93 million. It is projected to garner US$ 659.34 million by 2028 to expand at 5.0% CAGR during 2022–2028.    

Based on country, the North America endothelial dysfunction market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 80.5% share of North America endothelial dysfunction market in 2022. It was assessed at US$ 766.34 million in 2022 and is likely to hit US$ 1,011.96 million by 2028, exhibiting a CAGR of 4.7% during 2022–2028.      

Key players operating in the North America endothelial dysfunction are ZOLL Medical Corp, Lawrence Berkeley National Laboratory, Endothelix Inc, Perimed AB, SMART Medical Ltd, Everist Health Inc, and Medizinische Messtechnik GmbH, among others.   

• In April 2023, Perimed has signed an agreement with Lovell Government Services. Lovell’s customers are Federal, State, and Local Governments such as the Department of Veteran Affairs (VA), Defense Logistics Agency, and Department of Defense in the United States. With this agreement, Perimed gains an additional sales channel as Lovell will notify the company of any government contract opportunities within its field of business and bid on Perimed’s behalf.
• In April 2021, Berkeley Lab has developed flow-mediated dilation device to monitor both endothelial function and endothelium-independent vasodilation.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com